Pricing
Prices are indicative MRP and may vary by pharmacy. Trend compares against the last recorded price.
All price changes →Save on this medicine
Same active ingredient — pay up to 33% less
These brands contain the same active ingredient (Empagliflozin + Linagliptin). Same strength and form. Confirm the switch with your doctor or pharmacist.
Adlina-EM
Rx10 mg+5 mg • Tablet
More from Adlina-EM
Other strengths and forms by Unimed Unihealth Pharmaceuticals Ltd.
Indications & Uses
Adlina-EM is indicated for:
Pharmacology
Linagliptin blocks the DPP-4 enzyme, which breaks down the incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). With the enzyme blocked, the level of active incretin hormones goes up. This stimulates the release of insulin in a glucose-dependent manner and lowers the level of glucagon. Both hormones take part in the body's normal regulation of glucose homeostasis. They are secreted at a low basal level through the day, and their levels rise straight after a meal. GLP-1 and GIP increase insulin biosynthesis and secretion from the pancreatic beta cells, whether blood glucose is normal or raised. GLP-1 also reduces glucagon secretion from the pancreatic alpha cells, and this lowers the glucose output from the liver. Empagliflozin inhibits the sodium-glucose co-transporter 2 (SGLT2). SGLT2 is the main transporter that takes glucose from the kidney back into the circulation. By blocking it, Empagliflozin reduces the kidney's reabsorption of filtered glucose and lowers the renal threshold for glucose, so more glucose is passed out in the urine.
Dosage Reference
Reference Information Only
Dosages shown are general references from official sources. Always consult your doctor or pharmacist for personalized dosing.
Adults:
The usual dose of Empagliflozin + Linagliptin is 10 mg Empagliflozin and 5 mg Linagliptin once daily. Take it in the morning, with or without food.
If needed, the dose can be raised to 25 mg Empagliflozin and 5 mg Linagliptin once daily.
For patients with impaired kidney function, check renal function before starting this tablet. Don't start it if eGFR is below 45 mL/min/1.73 m2. If eGFR falls below 45 mL/min/1.73 m2 while the patient is already taking it, stop the tablet.
Side Effects
Empagliflozin + Linagliptin has several important side effects, and each one is described below and in other parts of the labeling. They are pancreatitis, ketoacidosis, volume depletion, urosepsis and pyelonephritis, hypoglycemia with concomitant use with insulin and insulin secretagogues, necrotizing fasciitis of the perineum (Fournier's gangrene), genital mycotic infections, hypersensitivity reactions, severe and disabling arthralgia, and bullous pemphigoid. Heart failure is also listed.
Cautions & Contraindications
Warnings & Precautions
Take care when using Empagliflozin + Linagliptin in people with certain conditions, such as pancreatitis, hypotension, ketoacidosis, acute kidney injury and impaired kidney function, urosepsis and pyelonephritis, hypoglycemia, genital mycotic infections and hypersensitivity. Pancreatitis Acute pancreatitis, including fatal pancreatitis, has been reported in patients treated with Linagliptin. Ketoacidosis Ketoacidosis is a serious, life-threatening condition that needs urgent hospitalization. Reports of it have come from clinical trials and postmarketing surveillance in patients with type 1 and type 2 diabetes mellitus who were receiving sodium glucose co-transporter-2 (SGLT2) inhibitors, including Empagliflozin. Fatal cases have been reported in patients taking Empagliflozin. Volume Depletion Empagliflozin can cause intravascular volume depletion. Sometimes this shows up as symptomatic hypotension or acute transient changes in creatinine. Urosepsis and Pyelonephritis There have been postmarketing reports of serious urinary tract infections, including urosepsis and pyelonephritis, that needed hospitalization in patients receiving SGLT2 inhibitors, including Empagliflozin. Treatment with SGLT2 inhibitors increases the risk of urinary tract infections. Hypoglycemia with Concomitant Use with Insulin & Insulin Secretagogues Insulin and insulin secretagogues are known to cause hypoglycemia. Necrotizing Fasciitis of the Perineum (Fournier's Gangrene) Necrotizing fasciitis of the perineum (Fournier's gangrene) is a rare but serious, life-threatening necrotizing infection that needs urgent surgical intervention. It has been identified in postmarketing surveillance in patients with diabetes mellitus receiving SGLT2 inhibitors, including Empagliflozin. Genital Mycotic Infections Empagliflozin increases the risk of genital mycotic infections. Hypersensitivity reactions, severe and disabling arthralgia, bullous pemphigoid Heart Failure In cardiovascular outcomes trials for two other members of the DPP-4 inhibitor class, an association between DPP-4 inhibitor treatment and heart failure has been observed. These trials evaluated patients with type 2 diabetes mellitus and atherosclerotic cardiovascular disease.
Contraindications
Empagliflozin + Linagliptin should not be used in people with severe renal impairment, end-stage renal disease, or those on dialysis. It is also contraindicated in anyone with a history of hypersensitivity reaction to Linagliptin, such as anaphylaxis, angioedema, exfoliative skin conditions, urticaria, or bronchial hyperreactivity. The same applies to anyone with a history of serious hypersensitivity reaction to Empagliflozin.
Pregnancy & Breastfeeding
Empagliflozin + Linagliptin is not recommended in the second and third trimesters of pregnancy. There isn't enough data on this tablet in pregnant women to say whether it carries a risk of major birth defects or miscarriage. Poorly controlled diabetes during pregnancy also carries risks for both the mother and the baby.
⚠️ Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.
Overdose
If someone takes too much of this Empagliflozin and Linagliptin tablet, contact a Poison Control Center. The usual supportive measures should be used, depending on the patient's clinical condition. These include removing any unabsorbed material from the gastrointestinal tract, monitoring the patient clinically, and starting supportive treatment. Whether Empagliflozin can be removed by hemodialysis has not been studied. Removal of Linagliptin by hemodialysis or peritoneal dialysis is unlikely.
⚠️ In an emergency call 999 or go to the nearest hospital emergency department.
Storage
Keep Empagliflozin + Linagliptin below 30° C. Protect it from light and from damp places. Keep it out of reach of children.
Drug Interactions
Common questions about Adlina-EM 10 mg+5 mg
What is Adlina-EM 10 mg+5 mg Tablet?
Adlina-EM 10 mg+5 mg Tablet is a medicine that contains Empagliflozin + Linagliptin. It is made by Unimed Unihealth Pharmaceuticals Ltd. It belongs to the Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors group of medicines.
What is Adlina-EM used for?
Adlina-EM is used for: Type 2 Diabetes Mellitus, Diabetes Mellitus.
What are the side effects of Adlina-EM?
Empagliflozin + Linagliptin has several important side effects, and each one is described below and in other parts of the labeling. They are pancreatitis, ketoacidosis, volume depletion, urosepsis and pyelonephritis, hypoglycemia with concomitant use with insulin and insulin secretagogues, necrotizing fasciitis of the perineum (Fournier's gangrene), genital mycotic infections, hypersensitivity reactions, severe and disabling arthralgia, and bullous pemphigoid.
Can I take Adlina-EM during pregnancy or while breastfeeding?
Empagliflozin + Linagliptin is not recommended in the second and third trimesters of pregnancy. There isn't enough data on this tablet in pregnant women to say whether it carries a risk of major birth defects or miscarriage. Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.
What happens if I take too much Adlina-EM?
If someone takes too much of this Empagliflozin and Linagliptin tablet, contact a Poison Control Center. The usual supportive measures should be used, depending on the patient's clinical condition. In an emergency call 999 or go to the nearest hospital emergency department.
How should I store Adlina-EM?
Keep Empagliflozin + Linagliptin below 30° C. Protect it from light and from damp places.
Can I take other medicines with Adlina-EM?
Some medicines can interact with Empagliflozin + Linagliptin, for example: Linagliptin, Empagliflozin, Insulin (Human) 30/70, Rifampicin. Tell your doctor or pharmacist about every medicine you take.
Is there a cheaper medicine with the same ingredient?
Empazin L by Delta Pharma PLC. has the same ingredient and strength for ৳20.00 per unit, compared with ৳30.00 for Adlina-EM. Ask your doctor or pharmacist before switching.
Do I need a prescription for Adlina-EM?
Adlina-EM is a prescription (Rx) medicine. Take it as your doctor advises.